Trice Medical™, a private medical device company focused on micro invasive technologies, today announced that it closed its Series B financing totaling $18.1 million. The company raised an additional $6.5 million to supplement the initial $11.6 million, which was announced in July 2014. HealthQuest Capital led the extension. Safeguard Scientifics, Inc. (NYSE:SFE) provided an additional $1.15 million in the extension to bring its total capital deployed to $6.15 million. BioStar Ventures and other existing investors completed the round. Proceeds will be used to support Trice Medical’s commercialization and marketing of its initial diagnostic arthroscopy product, mi-eye™, into the physician’s office. HealthQuest partner Garheng Kong, MD, PhD will join Trice's Board of Directors and HealthQuest partner Randy Scott will join as a Board observer.